Septerna (NASDAQ:SEPN) Reaches New 52-Week Low – Time to Sell?

Septerna, Inc. (NASDAQ:SEPN)’s share price reached a new 52-week low during trading on Saturday . The company traded as low as $17.71 and last traded at $17.99, with a volume of 207078 shares changing hands. The stock had previously closed at $20.85.

Analyst Ratings Changes

Several brokerages have issued reports on SEPN. TD Cowen began coverage on Septerna in a research report on Tuesday, November 19th. They issued a “buy” rating on the stock. JPMorgan Chase & Co. assumed coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 target price for the company. Wells Fargo & Company assumed coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 price target on the stock. Finally, Cantor Fitzgerald began coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $50.00 price objective for the company.

Septerna Stock Down 13.7 %

The company’s 50 day moving average is $23.63.

Insider Buying and Selling at Septerna

In other Septerna news, major shareholder Rock Ventures V. L.P. Third acquired 370,500 shares of the stock in a transaction dated Monday, October 28th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $6,669,000.00. Following the completion of the transaction, the insider now directly owns 6,215,591 shares of the company’s stock, valued at approximately $111,880,638. The trade was a 6.34 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.